Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 3/2005

01.09.2005 | Original Article

Potential for drug interactions in hospitalized cancer patients

verfasst von: Rachel Pimenta Riechelmann, Frederico Moreira, Òren Smaletz, Everardo D. Saad

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To quantify the frequency of potential drug interactions unrelated to chemotherapy in cancer patients admitted to our institution, and to define risk factors for such interactions.

Methods

Charts of 100 consecutive hospitalized cancer patients were reviewed. Patients receiving chemotherapy and/or hormone therapy were excluded, as were patients admitted for intensive care. Drug–drug interactions were screened with Drug Interaction Facts software, and manually by the authors. Potential interactions were graded by levels of severity (severe, moderate, minor) and significance (one to five, with one representing the highest level of evidence).

Results

The median age of the patients was 67 years, and the length of hospital stay and the number of drugs per patient were 6 days and eight drugs, respectively. In 63 patients 180 potential interactions were detected. Of the potential interactions, 18.3% were severe, 56.7% were moderate, and 25% were minor. Approximately 7%, 18% and 13% of potential interactions were graded as level 1, 2 and 3, respectively. In multivariate analysis, prescriptions with eight or more drugs (P=0.0004) and six or more days of hospital stay (P=0.014) were independent risk factors for potential interactions.

Conclusion

Potential drug interactions are common among hospitalized cancer patients. Length of hospital stay and number of prescribed drugs are risk factors.
Literatur
1.
Zurück zum Zitat Barrons R (2004) Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm 61:380–385 Barrons R (2004) Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm 61:380–385
2.
Zurück zum Zitat Beers MH, Storrie M, Lee G (1990) Potential adverse drug interactions in the emergency room. An issue in the quality of care. Ann Intern Med 112:61–64 Beers MH, Storrie M, Lee G (1990) Potential adverse drug interactions in the emergency room. An issue in the quality of care. Ann Intern Med 112:61–64
3.
Zurück zum Zitat Bernard S, Bruera E (2000) Drug interactions in palliative care. J Clin Oncol 18:1780–1799 Bernard S, Bruera E (2000) Drug interactions in palliative care. J Clin Oncol 18:1780–1799
4.
Zurück zum Zitat Bjerrum L, Andersen M, Petersen G, Kragstrup J (2003) Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 21:153–158CrossRefPubMed Bjerrum L, Andersen M, Petersen G, Kragstrup J (2003) Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 21:153–158CrossRefPubMed
5.
Zurück zum Zitat Buajordet I, Ebbesen J, Erikssen J, Brors O, Hilberg T (2001) Fatal adverse drug events: the paradox of drug treatment. J Intern Med 250:327–341 Buajordet I, Ebbesen J, Erikssen J, Brors O, Hilberg T (2001) Fatal adverse drug events: the paradox of drug treatment. J Intern Med 250:327–341
6.
Zurück zum Zitat Carbonin P, Pahor M, Bernabei R, Sgadari A (1991) Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc 39:1093–1099PubMed Carbonin P, Pahor M, Bernabei R, Sgadari A (1991) Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc 39:1093–1099PubMed
7.
Zurück zum Zitat Ciummo PE, Katz NL (1995) Interactions and drug-metabolizing enzymes. Am Pharm NS35:41–51; quiz 51–53 Ciummo PE, Katz NL (1995) Interactions and drug-metabolizing enzymes. Am Pharm NS35:41–51; quiz 51–53
8.
Zurück zum Zitat Corcoran ME (1997) Polypharmacy in the older patient with cancer. Cancer Control 4:419–428 Corcoran ME (1997) Polypharmacy in the older patient with cancer. Cancer Control 4:419–428
9.
Zurück zum Zitat Craig C, Stiztel R (1997) Modern pharmacology with clinical application, 5th edn. Little Brown and Company, New York Craig C, Stiztel R (1997) Modern pharmacology with clinical application, 5th edn. Little Brown and Company, New York
10.
Zurück zum Zitat Daly MP, Lamy PP, Richardson JP (1994) Avoiding polypharmacy and iatrogenesis in the nursing home. Md Med J 43:139–144 Daly MP, Lamy PP, Richardson JP (1994) Avoiding polypharmacy and iatrogenesis in the nursing home. Md Med J 43:139–144
11.
Zurück zum Zitat Davidson KW, Kahn A, Price RD (1987) Reduction of adverse drug reactions by computerized drug interaction screening. J Fam Pract 25:371–375 Davidson KW, Kahn A, Price RD (1987) Reduction of adverse drug reactions by computerized drug interaction screening. J Fam Pract 25:371–375
12.
Zurück zum Zitat Delafuente JC (2003) Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol 48:133–143 Delafuente JC (2003) Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol 48:133–143
14.
Zurück zum Zitat Egger SS, Drewe J, Schlienger RG (2003) Potential drug–drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 58:773–778PubMed Egger SS, Drewe J, Schlienger RG (2003) Potential drug–drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 58:773–778PubMed
15.
Zurück zum Zitat Fauno P, Petersen KD, Husted SE (1993) Increased blood loss after preoperative NSAID. Retrospective study of 186 hip arthroplasties. Acta Orthop Scand 64:522–524 Fauno P, Petersen KD, Husted SE (1993) Increased blood loss after preoperative NSAID. Retrospective study of 186 hip arthroplasties. Acta Orthop Scand 64:522–524
16.
Zurück zum Zitat Gear RW, Miaskowski C, Heller PH, Paul SM, Gordon NC, Levine JD (1997) Benzodiazepine mediated antagonism of opioid analgesia. Pain 71:25–29 Gear RW, Miaskowski C, Heller PH, Paul SM, Gordon NC, Levine JD (1997) Benzodiazepine mediated antagonism of opioid analgesia. Pain 71:25–29
17.
Zurück zum Zitat Geppert U, Beindl W, Hawranek T, Hintner H (2003) Drug interactions in clinical practice. A pilot project for quality assurance in prescribing. Hautarzt 54:53–57 Geppert U, Beindl W, Hawranek T, Hintner H (2003) Drug interactions in clinical practice. A pilot project for quality assurance in prescribing. Hautarzt 54:53–57
18.
Zurück zum Zitat Gerson LB, Triadafilopoulos G (2001) Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 13:611–616 Gerson LB, Triadafilopoulos G (2001) Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 13:611–616
19.
Zurück zum Zitat Glassman PA, Simon B, Belperio P, Lanto A (2002) Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 40:1161–1171CrossRefPubMed Glassman PA, Simon B, Belperio P, Lanto A (2002) Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 40:1161–1171CrossRefPubMed
20.
Zurück zum Zitat Goldberg RM, Mabee J, Mammone M, Chan L, Tarleton G, Broderick S, Robinson DC, Hurst AK, Whelan GP (1994) A comparison of drug interaction software programs: applicability to the emergency department. Ann Emerg Med 24:619–625 Goldberg RM, Mabee J, Mammone M, Chan L, Tarleton G, Broderick S, Robinson DC, Hurst AK, Whelan GP (1994) A comparison of drug interaction software programs: applicability to the emergency department. Ann Emerg Med 24:619–625
21.
Zurück zum Zitat Goldberg RM, Mabee J, Chan L, Wong S (1996) Drug–drug and drug–disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 14:447–450 Goldberg RM, Mabee J, Chan L, Wong S (1996) Drug–drug and drug–disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 14:447–450
22.
Zurück zum Zitat Hancock D, Kennington JM, Beckner RR, Quick G (1992) Emergency department medication and drug interaction evaluation. Hosp Pharm 27:129–132 Hancock D, Kennington JM, Beckner RR, Quick G (1992) Emergency department medication and drug interaction evaluation. Hosp Pharm 27:129–132
23.
Zurück zum Zitat Heininger-Rothbucher D, Bischinger S, Ulmer H, Pechlaner C, Speer G, Wiedermann CJ (2001) Incidence and risk of potential adverse drug interactions in the emergency room. Resuscitation 49:283–288 Heininger-Rothbucher D, Bischinger S, Ulmer H, Pechlaner C, Speer G, Wiedermann CJ (2001) Incidence and risk of potential adverse drug interactions in the emergency room. Resuscitation 49:283–288
24.
Zurück zum Zitat Herr RD, Caravati EM, Tyler LS, Iorg E, Linscott MS (1992) Prospective evaluation of adverse drug interactions in the emergency department. Ann Emerg Med 21:1331–1336 Herr RD, Caravati EM, Tyler LS, Iorg E, Linscott MS (1992) Prospective evaluation of adverse drug interactions in the emergency department. Ann Emerg Med 21:1331–1336
25.
Zurück zum Zitat Hosmer DW, Lemeshow S (1989) Applied logistic regression. Wiley, New York Hosmer DW, Lemeshow S (1989) Applied logistic regression. Wiley, New York
26.
Zurück zum Zitat Jankel CA, Martin BC (1992) Evaluation of six computerized drug interaction screening programs. Am J Hosp Pharm 49:1430–1435 Jankel CA, Martin BC (1992) Evaluation of six computerized drug interaction screening programs. Am J Hosp Pharm 49:1430–1435
27.
Zurück zum Zitat Karas S Jr (1981) The potential for drug interactions. Ann Emerg Med 10:627–630 Karas S Jr (1981) The potential for drug interactions. Ann Emerg Med 10:627–630
28.
Zurück zum Zitat Lackner TE (1991) Interaction of dexamethasone with phenytoin. Pharmacotherapy 11:344–347 Lackner TE (1991) Interaction of dexamethasone with phenytoin. Pharmacotherapy 11:344–347
29.
Zurück zum Zitat McLeod HL (1998) Clinically relevant drug–drug interactions in oncology. Br J Clin Pharmacol 45:539–544 McLeod HL (1998) Clinically relevant drug–drug interactions in oncology. Br J Clin Pharmacol 45:539–544
30.
Zurück zum Zitat Michocki RJ, Lamy PP, Hooper FJ, Richardson JP (1993) Drug prescribing for the elderly. Arch Fam Med 2:441–444 Michocki RJ, Lamy PP, Hooper FJ, Richardson JP (1993) Drug prescribing for the elderly. Arch Fam Med 2:441–444
31.
Zurück zum Zitat Pick CG (1997) Antinociceptive interaction between alprazolam and opioids. Brain Res Bull 42:239–243 Pick CG (1997) Antinociceptive interaction between alprazolam and opioids. Brain Res Bull 42:239–243
32.
Zurück zum Zitat Poirier TI, Giudici R (1995) Evaluation of drug interaction microcomputer software: an updated comparison. Hosp Pharm 30:888–890, 893–894 Poirier TI, Giudici R (1995) Evaluation of drug interaction microcomputer software: an updated comparison. Hosp Pharm 30:888–890, 893–894
33.
Zurück zum Zitat Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148:705–713 Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148:705–713
34.
Zurück zum Zitat Tatro DS (ed) (1997) Drug interaction facts, 4th edn. Facts and Comparisons, St. Louis, MO Tatro DS (ed) (1997) Drug interaction facts, 4th edn. Facts and Comparisons, St. Louis, MO
35.
Zurück zum Zitat Weale AE, Warwick DJ, Durant N, Prothero D (1995) Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement? Ann R Coll Surg Engl 77:35–37 Weale AE, Warwick DJ, Durant N, Prothero D (1995) Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement? Ann R Coll Surg Engl 77:35–37
Metadaten
Titel
Potential for drug interactions in hospitalized cancer patients
verfasst von
Rachel Pimenta Riechelmann
Frederico Moreira
Òren Smaletz
Everardo D. Saad
Publikationsdatum
01.09.2005
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 3/2005
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-004-0998-4

Weitere Artikel der Ausgabe 3/2005

Cancer Chemotherapy and Pharmacology 3/2005 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.